Today we are a great international Group

Our history started many years ago

0
1968

Foundation of SORIN, a nuclear energy production center in Saluggia (Vercelli, Italy), by a JV between FIAT and Montecatini

The opening of Europe’s first in vitro diagnostics center

1997

DiaSorin, the diagnostics division of SORIN Group, is sold to the multinational American Standard International

2000

A management buyout brings DiaSorin ownership back to Italy

2007

On July 19, DiaSorin is listed on the Italian stock exchange (Piazza Affari, Milan)

2010-2015

DiaSorin continues to grow organically and inorganically, expanding geographically and investing in technology and product innovation. It forms numerous partnerships with leading players in the global diagnostics market (Roche, Beckman Coulter, Meridian Bioscience)

2016

DiaSorin enters the molecular diagnostics sector by acquiring the American Focus Diagnostics, now DiaSorin Molecular, adding to the Group’s competence and excellence

2018

DiaSorin included in the FTSE MIB

DiaSorin enters a partnership with Qiagen for latent tuberculosis testing

DiaSorin acquires Siemens Healthineers’ ELISA business

2020

DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution

2021

DiaSorin launches the LIAISON IQ analyzer with Lumos Diagnostics for POC immunodiagnostics

DiaSorin acquires the US company Luminex Corporation for $1.8bn, thus gaining multiplexing technology for molecular diagnostics and that in the Licensed Technology field

DiaSorin launches the Lyme test in partnership with QIAGEN and the MeMed BV test in partnership with MeMed